E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
POST SURGICAL HYPOCALCEMIA |
IPOCALCEMIA POST CHIRURGICA |
|
E.1.1.1 | Medical condition in easily understood language |
patients with high risk of hypocalcemia after thyroid surgery. |
PAZIENTI SOTTOPOSTI A INTERVENTO DI TIROIDECTOMIA TOTALE CON ALTO RISCHIO DI SVILUPPARE IPOCALCEMIA POST-CHIRURGICA |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033557 |
E.1.2 | Term | Palpitations |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021097 |
E.1.2 | Term | Hypotension |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037087 |
E.1.2 | Term | Pruritus |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
to evaluate if teriparatide is able to prevent post-surgical hypocalcemia in subjects with high risk of hypocalcemia after thyroid surgery. |
VALUTARE SE LA TERIPARATIDE E' IN GRADO DI PREVENIRE LO SVILUPPO DI IPOCALCEMIA POST CHIRURGICA |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
surgical indication for thyroidectomy |
PAZIENTI CON INDICAZIONE AD INTERVENTO DI TIROIDECTOMIA TOTALE |
|
E.4 | Principal exclusion criteria |
-Age younger than 18 years - Pregnancy - Renal failure (glomerular filtration rate < 30 mL/min) - Hypersensitivity to the active substance or excipients - Any prior parathyroid pathology - Familiar history of Osteosarcoma or any other bone tumors - Preexisting hypercalcemia - Symptomatic orthostatic hypotension - Metabolic bone disease other than osteoporosis - Ongoing teriparatide therapy for osteoporosis - History of skeletal malignancies (primary or metastatic) - Treatment with digoxin (digitalis therapy) - Active or recent urolithiasis - Unexplained elevation of serum alkaline phosphatase levels - Prior radiation therapy involving the skeleton |
-ETA' MINORE DI 18 ANNI -GRAVIDANZA -INSUFFICIENZA RENALE (GRF< 30 mL/min) -IPERSENSIBILITA' AL PRINCIPIO ATTIVO O AGLI ECCIPIENTI -PATOLOGIE PARATIROIDEE PREGRESSE -STORIA FAMILIARE DI OSTEOSARCOMA O ALTRO TUMORE DELLE OSSA -PREGRESSA IPERCALCEMIA -IPOTENSIONE ORTOSTATICA SINTOMATICA -MALATTIE METABOLICHE OSSEE AD ECCEZIONE DELL'OSTEOPOROSI -TERAPIA IN ATTO CON TERIPARATIDE PER OSTEOPOROSI - STORIA DI MALATTIE MALIGNE OSSEE (PRIMITIVE O METASTATICHE) -TRATTAMENTO CON DIGOSSINA (TERAPIA DIGITALE) -RECENTE UROLITIASI -INSPIEGABILE INNALZAMENTO DEI VALORI SIERICI DI FOSFATASI ALCALINA - RADIOTERAPIA CON INTERESSAMENTO DELLO SCHELETRO |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in calcium levels from the enrollment to the discharge |
Monitoraggio dei livelli di calcio dall'arruolamento alla dimissione. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
every 12 hours till to discharge |
ogni 12 ore fino alla dimissione |
|
E.5.2 | Secondary end point(s) |
reduction of duration of the hospitalization |
riduzione dei tempi di ospedalizzazione |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
at the discharge |
alla dimissione |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
sorveglianza medica |
monitoring |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 36 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 36 |